Literature DB >> 1175271

Correlation of plasma propranolol concentration with therapeutic response in patients with angina pectoris.

M Pine, L Favrot, S Smith, K McDonald, C A Chidsey.   

Abstract

The therapeutic response to propranolol was evaluated in patients with documented coronary artery disease at doses varying from 40 to 320 mg/day. Therapeutic response was quantified by evaluating exercise performance on a treadmill and then related to plasma propranolol concentration. Plasma propranolol was defined in terms of beta-adrenergic blockade by comparison with dose (concentration) response curves in normal subjects. Individual therapeutic benefit occurred at doses which averaged 144 +/- 21 mg/day and at concentrations which averaged 30 +/- 7 ng/ml. There was a wide variation between both dose and concentration among the patients at maximum therapeutic response, but when the plasma propranolol was related to pharmacologic activity, the maximum therapeutic response was observed between 64 to 98% of total blockade. Despite the increased exercise performance in these patients, the double product of heart rate and systolic blood pressure was always less, suggesting either an alteration of the relation between myocardial oxygen consumption and the double product during propranolol or a reduction on oxygen delivery to the myocardium as the result of beta-adrenergic blockade of the coronary vasculature.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1175271     DOI: 10.1161/01.cir.52.5.886

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  25 in total

Review 1.  Risk assessment of adverse pulmonary effects induced by adrenaline beta-receptor antagonists and rational drug dosage regimen based on receptor occupancy.

Authors:  Y Yamada; K Matsuyama; K Ito; Y Sawada; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1995-10

2.  Pharmacokinetic and pharmacodynamic comparison of two doses of long acting propranolol (80 and 160 mg) in healthy subjects.

Authors:  B Flouvat; I Berlin; A Cournot; D Robinet; J Duchier; H Sarmini; A Rossi
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

3.  Once daily administration of sustained release propranolol capsules in the treatment of angina pectoris.

Authors:  H Halkin; I Vered; A Saginer; B Rabinowitz
Journal:  Eur J Clin Pharmacol       Date:  1979       Impact factor: 2.953

4.  Concentration-effect relationships with FM 24: a new long acting beta-adrenergic receptor antagonist.

Authors:  C T Dollery; H J Dargie; J Sassard; G Cuisinaud
Journal:  Br J Clin Pharmacol       Date:  1983-06       Impact factor: 4.335

Review 5.  Exercise performance and beta-blockade.

Authors:  P A Tesch
Journal:  Sports Med       Date:  1985 Nov-Dec       Impact factor: 11.136

6.  The effect of propranolol on exercise induced tachycardia is determined by plasma concentration and the density of adrenergic receptors on leukocytes.

Authors:  K Tawara; E Steiner; C von Bahr
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 7.  Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies.

Authors:  P Pentel; N Benowitz
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

8.  Effect of oral propranolol on rest and exercise left ventricular ejection fraction, volumes, and segmental wall motion in patients with angina pectoris. Assessment with equilibrium gated blood pool imaging.

Authors:  G J Dehmer; M Falkoff; S E Lewis; L D Hillis; R W Parkey; J T Willerson
Journal:  Br Heart J       Date:  1981-06

9.  Comparison of antianginal efficacy of one conventional and three long acting beta-adrenoreceptor blocking agents in stable angina pectoris.

Authors:  G R Jones; M A Mir
Journal:  Br Heart J       Date:  1981-11

10.  Clinical pharmacokinetics of buffered propranolol sublingual tablet (Promptol™)-application of a new "physiologically based" model to assess absorption and disposition.

Authors:  Yanfeng Wang; Zhijun Wang; Zhong Zuo; Brian Tomlinson; Benjamin T K Lee; Michael B Bolger; Moses S S Chow
Journal:  AAPS J       Date:  2013-04-19       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.